Distinct structural changes in the GABAA receptor elicited by pentobarbital and GABA.
The barbiturate pentobarbital binds to gamma-aminobutyric acid type A (GABA(A)) receptors, and this interaction plays an important role in the anesthetic action of this drug. Depending on its concentration, pentobarbital can potentiate (approximately 10-100 microM), activate (approximately 100-800 microM), or block (approximately 1-10 mM) the channel, but the mechanisms underlying these three distinct actions are poorly understood. To investigate the drug-induced structural rearrangements in the GABA(A) receptor, we labeled cysteine mutant receptors expressed in Xenopus oocytes with the sulfhydryl-reactive, environmentally sensitive fluorescent probe tetramethylrhodamine-6-maleimide (TMRM). We then used combined voltage clamp and fluorometry to monitor pentobarbital-induced channel activity and local protein movements simultaneously in real time. High concentrations of pentobarbital induced a decrease in TMRM fluorescence (F(TMRM)) of labels tethered to two residues in the extracellular domain (alpha(1)L127C and beta(2)L125C) that have been shown previously to produce an increase in F(TMRM) in response to GABA. Label at beta(2)K274C in the extracellular end of the M2 transmembrane helix reported a small but significant F(TMRM) increase during application of low modulating pentobarbital concentrations, and it showed a much greater F(TMRM) increase at higher concentrations. In contrast, GABA decreased F(TMRM) at this site. These results indicate that GABA and pentobarbital induce different structural rearrangements in the receptor, and thus activate the receptor by different mechanisms. Labels at alpha(1)L127C and beta(2)K274C change their fluorescence by substantial amounts during channel blockade by pentobarbital. In contrast, picrotoxin blockade produces no change in F(TMRM) at these sites, and the pattern of F(TMRM) signals elicited by the antagonist SR95531 differs from that produced by other antagonists. Thus, with either channel block by antagonists or activation by agonists, the structural changes in the GABA(A) receptor protein differ during transitions that are functionally equivalent.
Muroi
Yukiko
Y
Department of Physiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Theusch
Cassandra M
CM
Czajkowski
Cynthia
C
Jackson
Meyer B
MB
D000704:Analysis of Variance; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005470:Fluorometry; D018757:GABA Modulators / Q000378:metabolism / Q000494:pharmacology*; D058787:GABA-A Receptor Antagonists; D008564:Membrane Potentials / Q000187:drug effects; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009865:Oocytes; D018408:Patch-Clamp Techniques; D010424:Pentobarbital / Q000494:pharmacology*; D010852:Picrotoxin / Q000494:pharmacology; D011487:Protein Conformation / Q000187:drug effects; D051381:Rats; D011963:Receptors, GABA-A / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D012235:Rhodamines / Q000378:metabolism; D014982:Xenopus laevis; D005680:gamma-Aminobutyric Acid / Q000737:chemistry / Q000378:metabolism*
D018757:GABA Modulators; D058787:GABA-A Receptor Antagonists; D010424:Pentobarbital; D010852:Picrotoxin; D011963:Receptors, GABA-A; D012235:Rhodamines; D005680:gamma-Aminobutyric Acid; C546242:Gabra1 protein, rat; C502185:Gabrb2 protein, rat; C546281:Gabrg2 protein, rat; C005358:tetramethylrhodamine